Login
Therapeutic Area
Metabolic
Respiratory
Cardiovascular
Products
All products
Metabolic
Jardiance
Glyxambi
Respiratory
OFEV
Cardiovascular
Resources
Contact
Login
CV Risk in T2D
EMPA-REG Outcome Trial
Safety
Safety
JARDIANCE can now be used down to an eGFR of 30 mL/min/1.73 m2
CRM
CRM
SGLT2i and CV Outcomes for Patients with CV Risk
EMPA-REG Trial Outcomes for T2D and CV Disease Patients
EMPA REG Trial Kidney Outcomes for T2D Patients
KDIGO Guidelines 2022 Update
Global Clinical Guidelines Recommendation for the Preferential Use of SGLT2 inhibitors in Patients with T2D and CKD
T2D is a Progressive Disease that requires a holistic approach
CV Risk Protection
MPR-PH-100058
Production date: May 2019
Close
×